Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Approves OZURDEX for Uveitis

September 29, 2010 7:15 am | News | Comments

Allergan, Inc. announced that the United States Food and Drug Administration has approved OZURDEX 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.


Galapagos Starts Phase 2 Trial for RA

September 29, 2010 7:04 am | News | Comments

Galapagos NV announced that it has started a Phase 2 clinical study for the company’s flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis.


Fostamatinib Helpful in RA Patients

September 29, 2010 6:58 am | News | Comments

AstraZeneca’s oral syk inhibitor, fostamatinib, in-licensed from Rigel Pharmaceuticals, Inc., significantly improved outcomes of patients with rheumatoid arthritis who responded inadequately to methotrexate, according to recently published phase 2 study data.


Movetis Begins Phase 3 Trial of Prucalopride

September 29, 2010 6:49 am | News | Comments

Movetis NV announces that it has started a phase 3 clinical trial with prucalopride in male patients with chronic constipation. Positive results from this clinical trial should allow Movetis to apply for expansion of the current label of Resolor.


Depomed Receives Milestone Payment from Covidien

September 29, 2010 6:44 am | News | Comments

Depomed received a $500,000 payment from its partner Covidien PLC, which has started human testing of an extended-release painkiller using its technology.


XOMA Completes Enrollment of Phase 2 Diabetes Trial

September 29, 2010 6:39 am | News | Comments

XOMA Ltd. announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes. XOMA 052 is a therapeutic antibody candidate that inhibits the inflammatory cytokine interleukin-1 beta.


Protein Expression

September 28, 2010 8:52 am | Product Releases | Comments

AMSBIO has announced Solu BL21 Competent E. coli, a significantly improved BL21 host strain for soluble mammalian protein expression.


Mass Spectrometer

September 28, 2010 8:50 am | Product Releases | Comments

The AB SCIEX TripleTOF 5600 System is a fast and sensitive high-resolution mass spectrometer for high-performance qualitative and quantitative analysis.


Microplate Mixer

September 28, 2010 8:46 am | Product Releases | Comments

Microsonic Systems has announced that its HENDRIX SM100 now serves four key applications: Compound solubilization, Sample thawing, Microplate mixing, and Magnetic particles/cells suspension.


GATC Biotech Plans to Sequence 100k Genomes By 2015

September 28, 2010 8:30 am | News | Comments

Within the next four years GATC Biotech plans to analyse 100,000 human genomes in particular for the pharmaceutical and diagnostic industry as well as for academic research.


Walgreen Income Up 8%

September 28, 2010 8:28 am | News | Comments

Walgreen Co., the largest drugstore chain in the U.S., said its net income rose 8 percent in the fiscal fourth quarter on higher prescription drug sales.


Chelsea Therapeutics Beginning RA Drug Trial

September 28, 2010 8:22 am | News | Comments

Chelsea Therapeutics International, Ltd. has initiated enrollment in a Phase 2 trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate in patients with rheumatoid arthritis who are experiencing an inadequate response to methotrexate.


Cytheris Registering Patients for INSPIRE 3

September 28, 2010 8:18 am | News | Comments

Cytheris SA announced that it has begun enrolling patients in a Phase 2 clinical trial evaluating the effect of repeated cycles of CYT107 in HIV-1 infected patients classified as immunological non-responders after at least 24 months of HAART.


Wider Statin Use Could Cut Costs in Long Run

September 28, 2010 7:47 am | News | Comments

A new analysis suggests that broader statin use among adult patients may be a cost-effective way to prevent heart attack and stroke.


SNPs Lead to Painful Aromatase Inhibitor Side Effects

September 28, 2010 7:44 am | News | Comments

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.